Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths

Investigative Radiology

Volumn 40, Issue 11, 2005, Pages 715-724

  Rohrer, Martin ^a   Bauer, Hans ^a   Mintorovitch, Jan ^b   Requardt, Martin ^c   Weinmann, Hanns Joachim ^a  

^a BAYER PHARMA AG   (Germany)

^b Berlex Laboratories   (United States)

^c SIEMENS AG   (Germany)

Author keywords

Comparative studies; Field strength dependence; MRI contrast media; Relaxivity

Indexed keywords

CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODENTERATE; GADODIAMIDE; GADOFOSVERET; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; MANGAFODIPIR; SOLVENT; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; WATER;

ARTICLE; COMPARATIVE STUDY; EVALUATION; MAGNETIC FIELD; NUCLEAR MAGNETIC RESONANCE IMAGING; PHANTOM; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; TEMPERATURE DEPENDENCE;

EID: 27544442176     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000184756.66360.d3     Document Type: Article

References (55)

1. Weinmann H-J, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol. 1984;142:619-624.
2. Claussen C, Laniado M, Schorner W, et al. Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. AJNR Am J Neuroradiol. 1985;6:669-674.
3. Carr DH, Brown J, Bydder GM, et al. Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet. 1984;1:484-486.
4. Runge VM, Carollo BR, Wolf CR, et al. Gd DTPA: a review of clinical indications in entral nervous system magnetic resonance imaging. Radiographics. 1989;9:929-958.
5. Runge VM, Wells JW. Update: safety, new applications, new MR agents. Top Magn Reson Imaging. 1995;7:181-195.
6. Magerstadt M, Gansow OA, Brechbiel MW, et al. Gd(DOTA): an alternative to Gd(DTPA) as a T1, 2 relaxation agent for NMR imaging or spectroscopy. Magn Reson Med. 1986;3:808-812.
7. Van Wagoner M, O'Toole M, Quay SC. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection. Invest Radiol. 1990;25(Suppl 1):S39-41.
8. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol. 2001;36:65-71.
9. Runge VM, Dean B, Lee C, et al. Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. J Magn Reson Imaging. 1991;1:47-56.
10. Adzamli K, Periasamy MP, Spiller M, et al. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. Invest Radiol. 1999;34:410-414.
11. Grossman R, Kuhn MJ, Maravilla K, et al. Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine. Acad Radiol. 1998;5(Suppl 1):S154-155; discussion S156.
12. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol. 1995;21:1-10.
13. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol. 2002;12:1550-1556.
14. Earls JP, Bluemke DA. New MR imaging contrast agents. Magn Reson Imaging Clin N Am. 1999;7:255-273.
15. Weinmann HJ, Ebert W, Misselwitz B, et al. Tissue-specific MR contrast agents. Eur J Radiol. 2003;46:33-44.
16. Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radial. 2004;39:394-405.
17. Kellar KE, Fujii DK, Gunther WH, et al. NC100150 Injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging. 2000;11:488-494.
18. Elizondo G, Fretz CJ, Stark DD, et al. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology. 1991;178:73-78.
19. Hamm B, Vogl TJ, Branding G, et al. Focal liver lesions: MR imaging with Mn-DPDP-initial clinical results in 40 patients. Radiology. 1992;182:167-174.
20. Bloembergen N, Morgan LO. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J Chem Phys. 1961;34:843-850.
21. Lauffer RB. Metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987;87:901-927.
22. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) Chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-2352.
23. Banci L, Bertini I, Luchinat C. Nuclear and Electron Relaxation: The Magnetic Nucleus-Unpaired Electron Coupling in Solution. Weinheim: VCH; 1991.
24. Bertini I, Luchinat C. NMR of Paramagnetic Substances. Coord Chem Rev. 1996;150:1-292.
25. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183:59-64.
26. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998;33:798-809.
27. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162.
28. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
29. EMRF (European Magnetic Resonance Forum Foundation) Recommendations for the nomenclature of MR imaging contrast agent terms. Acta Radiol. 1997;38:5.
30. Niendorf HP, Laniado M, Semmler W, et al. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol. 1987;8:803-815.
31. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol. 1999;9:998-1004.
32. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol. 1992;13:1199-1206.
33. Elster AD. How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence. Eur Radiol. 1997;7(Suppl 5):276-280.
34. Reimer P, Muller M, Marx C, et al. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration-preliminary clinical experience with dynamic T1-weighted MR imaging. Radiology. 1998;209:831-836.
35. Bjemer T, Johansson L, Wikstrom G, et al. In and ex vivo MR evaluation of acute myocardial ischemia in pigs by determining R1 in steady state after the administration of the intravascular contrast agent NC100150 injection. Invest Radiol. 2004;39:479-486.
36. Donahue KM, Burstein D, Manning WJ, et al. Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med. 1994;32:66-76.
37. Judd RM, Reeder SB, May-Newman K. Effects of water exchange on the measurement of myocardial perfusion using paramagnetic contrast agents. Magn Reson Med. 1999;41:334-342.
38. Goyen M, Herborn CU, Vogt FM, et al. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging. 2003;17:565-571.
39. Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radial. 2004;14(Suppl 5):M12-M18.
40. Herborn CU, Lauenstein TC, Ruehm SG, et al. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol. 2003;38:27-33.
41. Fink C, Puderbach M, Ley S, et al. Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol. 2004;39:143-148.
42. Ibrahim MA, Emerson JF, Cotman CW. Magnetic resonance imaging relaxation times and gadolinium-DTPA relaxivity values in human cerebrospinal fluid. Invest Radiol. 1998;33:153-162.
43. Mandry D, Pedersen M, Odille F, et al. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in Sprague-Dawley rats. Invest Radiol. 2005;40:295-305.
44. Murphy PS, Leach MO, Rowland IJ. The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. Phys Med Biol. 2002;47:N53-N59.
45. Schnorr J, Wagner S, Abramjuk C, et al. Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol. 2004;39:546-553.
46. Muller RN, Gillis P, Moiny F, et al. Transverse relaxivity of paniculate MRI contrast media: from theories to experiments. Magn Reson Med. 1991;22:178-182; discussion 195-196.
47. Knopp MV, von Tengg-Kobligk H, Floemer F, et al. Contrast agents for MRA: future directions. J Magn Reson Imaging. 1999;10:314-316.
48. Vander Elst L, Laurent S, Muller RN. Multinuclear magnetic resonance characterization of paramagnetic contrast agents. The manifold effects of concentration and counterions. Invest Radiol. 1998;33:828-834.
49. Craik DJ, Levy GC. Factors affecting Accuracy in 13C Spin-Lattice Relaxation Measurements. In: Levy GC, ed. Topics in Carbon-13 NMR Spectroscopy. New York: Wiley; 1984;239-274.
50. Carrington A, McLachlan AD. Introduction to Magnetic Resonance with Applications to Chemistry and Chemical Physics. New York: Harper & Row; 1979.
51. Farrar TC, Becker ED. Pulse and Fourier Transform NMR. New York: Academic Press; 1971.
52. Fullerton GD, Potter JL, Dombluth NC. NMR relaxation of protons in tissues and other macromolecular water solutions. Magn Reson Imaging. 1982;1:209-226.
53. de Haen C, Calabi L, La Ferla R. The problematic determination of proton magnetic relaxation rates of protein-containing solutions. Acad Radiol. 2002;9(Suppl 1):S2-S4.
54. Weinmann HJ, Bauer H, Ebert W, et al. Comparative studies on the efficacy of MRI contrast agents in MRA. Acad Radiol. 2002;9(Suppl 1):S135-136.
55. 1 relaxation on the first-pass response. Magn Reson Med. 2002;47:298-304.